TRIB Kronos AI forecast
A 30-trading-day price forecast for Trinity Biotech plc American Depositary Shares (TRIB) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Trinity Biotech plc American Depositary Shares at $8.57 on 2026-12-08, +19.9% from the last close of $7.15 on 2026-10-27. Eight out of ten sampled paths end between $8.36 and $10.53, and 8 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of TRIB
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $8.24 | $7.17 | $9.45 |
| 2026-11-10 | $8.87 | $8.38 | $9.54 |
| 2026-11-17 | $8.93 | $8.00 | $9.80 |
| 2026-11-24 | $9.03 | $8.10 | $9.71 |
| 2026-12-01 | $8.94 | $7.71 | $9.56 |
| 2026-12-08 | $8.57 | $8.36 | $10.53 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for TRIB?
- Kronos AI's median forecast for TRIB is $8.57 in 30 trading days, +19.9% from the last close, with a 10–90% range of $8.36 to $10.53.
- Is the TRIB Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- IDXX — IDEXX Laboratories Inc.
- LNTH — Lantheus Holdings Inc.
- ORKA — Oruka Therapeutics Inc.
- NEOG — Neogen Corporation
- CLDX — Celldex Therapeutics Inc.
- NTLA — Intellia Therapeutics Inc.